295 related articles for article (PubMed ID: 25562777)
1. The US Food and Drug Administration's perspective on the new antidepressant vortioxetine.
Zhang J; Mathis MV; Sellers JW; Kordzakhia G; Jackson AJ; Dow A; Yang P; Fossom L; Zhu H; Patel H; Unger EF; Temple RJ
J Clin Psychiatry; 2015 Jan; 76(1):8-14. PubMed ID: 25562777
[TBL] [Abstract][Full Text] [Related]
2. Vilazodone: clinical basis for the US Food and Drug Administration's approval of a new antidepressant.
Laughren TP; Gobburu J; Temple RJ; Unger EF; Bhattaram A; Dinh PV; Fossom L; Hung HM; Klimek V; Lee JE; Levin RL; Lindberg CY; Mathis M; Rosloff BN; Wang SJ; Wang Y; Yang P; Yu B; Zhang H; Zhang L; Zineh I
J Clin Psychiatry; 2011 Sep; 72(9):1166-73. PubMed ID: 21951984
[TBL] [Abstract][Full Text] [Related]
3. Vortioxetine: A multimodal antidepressant or another selective serotonin reuptake inhibitor?
Keks NA; Hope J; Culhane C
Australas Psychiatry; 2015 Jun; 23(3):210-3. PubMed ID: 25907797
[TBL] [Abstract][Full Text] [Related]
4. Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction.
Jacobsen PL; Mahableshwarkar AR; Chen Y; Chrones L; Clayton AH
J Sex Med; 2015 Oct; 12(10):2036-48. PubMed ID: 26331383
[TBL] [Abstract][Full Text] [Related]
5. Vortioxetine: a New Treatment for Major Depressive Disorder.
Connolly KR; Thase ME
Expert Opin Pharmacother; 2016; 17(3):421-31. PubMed ID: 26679430
[TBL] [Abstract][Full Text] [Related]
6. Treatment-emergent sexual dysfunction in randomized trials of vortioxetine for major depressive disorder or generalized anxiety disorder: a pooled analysis.
Jacobsen PL; Mahableshwarkar AR; Palo WA; Chen Y; Dragheim M; Clayton AH
CNS Spectr; 2016 Oct; 21(5):367-378. PubMed ID: 26575433
[TBL] [Abstract][Full Text] [Related]
7. Randomized, 8-week, double-blind, placebo-controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52-week open-label extension trial.
Inoue T; Nishimura A; Sasai K; Kitagawa T
Psychiatry Clin Neurosci; 2018 Feb; 72(2):103-115. PubMed ID: 29160598
[TBL] [Abstract][Full Text] [Related]
8. US Food and Drug Administration's review of the novel antidepressant vortioxetine.
Thase ME
J Clin Psychiatry; 2015 Jan; 76(1):e120-1. PubMed ID: 25650679
[No Abstract] [Full Text] [Related]
9. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2014 Jan; 68(1):60-82. PubMed ID: 24165478
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder.
Mahableshwarkar AR; Jacobsen PL; Serenko M; Chen Y; Trivedi MH
J Clin Psychiatry; 2015 May; 76(5):583-91. PubMed ID: 26035186
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder.
Jacobsen PL; Mahableshwarkar AR; Serenko M; Chan S; Trivedi MH
J Clin Psychiatry; 2015 May; 76(5):575-82. PubMed ID: 26035185
[TBL] [Abstract][Full Text] [Related]
12. Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder.
Nishimura A; Aritomi Y; Sasai K; Kitagawa T; Mahableshwarkar AR
Psychiatry Clin Neurosci; 2018 Feb; 72(2):64-72. PubMed ID: 28858412
[TBL] [Abstract][Full Text] [Related]
13. Vortioxetine (Brintellix) for depression.
Med Lett Drugs Ther; 2013 Nov; 55(1430):93-5. PubMed ID: 24276501
[No Abstract] [Full Text] [Related]
14. Vortioxetine versus placebo in major depressive disorder comorbid with social anxiety disorder.
Liebowitz MR; Careri J; Blatt K; Draine A; Morita J; Moran M; Hanover R
Depress Anxiety; 2017 Dec; 34(12):1164-1172. PubMed ID: 29166552
[TBL] [Abstract][Full Text] [Related]
15. Vortioxetine: first global approval.
Gibb A; Deeks ED
Drugs; 2014 Jan; 74(1):135-45. PubMed ID: 24311349
[TBL] [Abstract][Full Text] [Related]
16. Other Antidepressants.
Schwasinger-Schmidt TE; Macaluso M
Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
[TBL] [Abstract][Full Text] [Related]
17. A Population Pharmacokinetic-Pharmacodynamic Meta-Analysis of Vortioxetine in Patients with Major Depressive Disorder.
Naik H; Chan S; Vakilynejad M; Chen G; Loft H; Mahableshwarkar AR; Areberg J
Basic Clin Pharmacol Toxicol; 2016 May; 118(5):344-55. PubMed ID: 26525043
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of different doses of three new antidepressants for treating major depressive disorder: A PRISMA-compliant meta-analysis.
He H; Wang W; Lyu J; Zheng J; Guo L; An X; Fan Y; Ma X
J Psychiatr Res; 2018 Jan; 96():247-259. PubMed ID: 29127931
[TBL] [Abstract][Full Text] [Related]
19. Vortioxetine : a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder.
Al-Sukhni M; Maruschak NA; McIntyre RS
Expert Opin Drug Saf; 2015 Aug; 14(8):1291-304. PubMed ID: 26022537
[TBL] [Abstract][Full Text] [Related]
20. VORTIOXETINE - THE NEW ANTIDEPRESSANT AGENT WITH PROCOGNITIVE PROPERTIES.
Dziwota E; Olajossy M
Acta Pol Pharm; 2016 Nov; 73(6):1433-1437. PubMed ID: 29634095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
